In April 2026, AB Science announced that it had reached a final agreement with its financial creditors. This agreement provides for a two-year deferral of the repayment of the State-Guaranteed Loans ...

MESQUITE, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- National Breathe Free is proud to welcome Metro ENT and Geetha Subramanian, MD, to its network of physician-led ear, nose and throat practices.

"The issue is not the sugar itself so much as how long it stays on the teeth," said Dr. Northcott. "Sticky candy glues itself to the enamel. A child who eats gummy candies and runs off to play is ...

HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) ...

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO ...

For more information and a complete agenda, please visit www.maximgrp.com/2026-growth-summit. About Filana Therapeutics, Inc.

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood ...

SkinHealth Systems (Nasdaq: SKIN) (the “Company”), home to flagship brand Hydrafacial™, today announced that its Board of Directors has approved a 1-for-20 reverse stock split (the “Reverse Stock ...

Oxford Brain Diagnostics (OBD), a pioneer in quantitative brain biology, today announced new research demonstrating that its Cortical Disarray Measurement (CDM®) technology reflected the distribution ...

A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com. About Nuvectis Pharma, Inc.

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the first ...